GlassScriptPhysician profile
Sarah C Passmore
NPI 1366002081
$6,475.16
in general payments reported to CMS, 2019-2025
51 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.22 · 2022: $685 · 2023: $3,178 · 2024: $1,427 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,765.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $2,237.65 | 2022-2024 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $585.83 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $290.49 | 2022-2025 | Libtayo |
| Celgene Corporation | $288.71 | 2023-2025 | Reblozyl |
| Janssen Biotech, INC. | $287.29 | 2022-2025 | Erleada, Akeega, Balversa |
| Incyte Corporation | $265.51 | 2022-2025 | Monjuvi, Jakafi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $248.31 | 2022-2025 | Ninlaro, Fruzaqla, Iclusig |
| Merck Sharp & Dohme LLC | $216.88 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $186.12 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Beigene USA, INC. | $139.16 | 2023-2025 | Brukinsa |
| Abbvie INC. | $130.08 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $127.15 | 2023-2025 | |
| Deciphera Pharmaceuticals INC. | $114.60 | 2022-2025 | Qinlock, Romvimza, Tgct |
| Seagen INC. | $102.90 | 2022-2023 | Tukysa, Padcev, Tivdak |
| Genentech USA, INC. | $80.08 | 2023-2025 | Polivy, Lunsumio, Tecentriq |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Passmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.